Guggenheim cuts Insmed stock price target on model changes to $201
Guggenheim reduced its price target for Insmed Inc. (INSM) to $201 from $205, citing model changes after Q3 2026 results. Brinsupri sales hit $400.1M, exceeding expectations, driving 240% revenue growth. Insmed's market cap is $24.7B. Arikayce also beat expectations. Goldman Sachs and Stifel maintained Buy ratings with targets of $194 and $195, respectively.
How this was made
The 30-second read
Why it matters
Analyst target adjustments reflect mixed view of growth versus profitability.
Market read
Post‑earnings analyst revisions provide modest guidance for traders.
What to watch
Potential pipeline progress and upcoming regulatory approvals could offset valuation concerns.
Background
Insmed reported Q3 2026 revenue of $524.4 million, beating forecasts, but EPS missed expectations.
Ticker impact
Guggenheim lowered its price target on Insmed to $201 from $205 following the company's Q3 2026 earnings release.
likely pressure as the market prices in the lower target
Target cut reflects concerns about valuation despite strong revenue; investors may trim positions.
Market effects
Biotech sector may see modest re‑rating as analysts reassess valuation multiples.
Limited to US‑listed biotech stocks.
Minimal global impact.
Counterpoint
Some investors may view the target cut as an over‑reaction given the strong revenue beat.
Key entities
- analystGuggenheim
Equity research firm that cut the price target.
- analystGoldman Sachs
Maintained a $194 price target.
- analystStifel
Adjusted target to $195.



